Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CHIT1 | Q13231 | 2/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.44 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836213 | 1.00 | KDM4E (0.58) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL6836225 | 0.92 | KDM4E (0.56) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL6841392 | 0.92 | KDM4E (0.56) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL6840856 | 0.91 | KDM4E (0.54) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL6840853 | 0.91 | KDM4E (0.54) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL27817743 | 0.87 | HTR2A (0.49) | KDM4EOPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL7023319 | 0.86 | KDM4E (0.52) | KDM4EGRIN2BSLC18A3SPHK1 | |
| SCHEMBL5689661 | 0.86 | KDM4E (0.52) | KDM4EGRIN2BSLC18A3SPHK1 | |
| SCHEMBL5689666 | 0.86 | KDM4E (0.52) | KDM4EGRIN2BSLC18A3SPHK1 | |
| SCHEMBL7046427 | 0.81 | HTR2A (0.63) | KDM4EGRIN2BHTR2ACHIT1CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6765022-B2 | BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; STROKES, PARKINSON*S DISEASE; N-METHYL-D-ASPARTATE ANTAGONISTS (NMDA) | WARNER-LAMBERT COMPANY | 2004-07-20 | — | — | US | claimed |
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-04 | — | — | US | claimed |
| US-6765022-B2 | BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS; ANTIISCHEMIC AGENTS; STROKES, PARKINSON*S DISEASE; N-METHYL-D-ASPARTATE ANTAGONISTS (NMDA) | WARNER-LAMBERT COMPANY | 2004-07-20 | — | — | US | disclosed |
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1296934-A1 | CYCLOHEXYLAMINE DERIVATIVES AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001092204-A1 | CYCLOHEXYLAMINE DERIVATIVES AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225164-A1 | Cyclohexylamine derivatives as subtype selective nmda receptor antagonists | GRIN1, GRIN3A, GRIN2A | KDM4E 2266/4885OPRM1 27/4885OPRD1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.